Besremi

Chemical Nameropeginterferon alfa-2b-njft
Dosage FormInjection (subcutaneous; 500 mcg/mL)
Drug ClassInterferons
SystemBlood
CompanyPharmaEssentia
Approval Year2021

Indication

  • For the treatment of adults with polycythemia vera.
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Besremi (ropeginterferon alfa-2b-njft) Prescribing Information.2021PharmaEssentia Corporation, Burlington, MA
Document TitleYearSource
Assessment report: Besremi.2021EMA